Phibro Animal Health Corporation
Phibro Animal Health Corp. develops, manufactures, and markets animal health and mineral nutrition products for food-producing animals and companion animals. It also sells selected performance products used in personal care, industrial chemicals, and chemical catalysts, with operations and distribution spanning the United States and many international markets.
Fiscal year 2026 · change from previous year
Development 2021–2026
Business
Share of revenueMedicines, vaccines, adjuvants, and related products for livestock and companion animals.
Mineral-based feed additives that support animal health and diet fortification.
Ingredients sold to personal care, industrial chemical, and catalyst customers.
Products
Reported · share of revenue- Medicated Feed Additives and Others53.4 %
- Mineral Nutrition18.6 %
- Nutritional Specialties12.8 %
- Vaccines10.3 %
- Performance Products4.8 %
Source: 10-K FY2026, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Phibro sells primarily to livestock producers, integrated poultry, swine, beef and dairy operations, animal feed manufacturers, veterinarians, nutritionists, wholesalers, and distributors. It also serves a smaller set of industrial customers that buy performance ingredients for personal care and chemical applications. The business is built around recurring demand from animal production cycles and technical support relationships with farm operators and veterinary channels.
Large poultry, swine, beef, and dairy operators buy health and nutrition products to manage herd and flock performance.
Feed companies buy mineral nutrition and specialty additives to fortify rations and improve animal outcomes.
They influence product selection and use animal health products in disease prevention and treatment programs.
They purchase and resell products in markets where Phibro lacks direct commercial presence.
Personal care, industrial chemical, and catalyst customers buy performance ingredients for formulation and processing.
Strategy
Phibro’s strategy centers on serving large commercial livestock producers with a broad portfolio that combines animal health and mineral nutrition. The company also uses technical support, distribution relationships, and cross-selling between product lines to deepen customer relationships and expand access to new accounts. A longer-term priority is building its companion animal presence while maintaining its core livestock franchise.
The core business is concentrated in poultry, swine, beef, and dairy, where scale and technical support matter.
Complementary products can increase wallet share and reduce customer concentration risk.
Companion animal products can diversify the portfolio beyond livestock cycles.
Geography
Phibro markets products in approximately 90 countries across North America, Latin America, Asia Pacific, Europe, Africa, and the Middle East. The company has a direct commercial presence in some markets and uses distributors in others, which broadens reach but also creates exposure to local regulation, import rules, and livestock-cycle differences. Its business is especially tied to regions with concentrated commercial livestock production.
Risks
Phibro is exposed to livestock disease outbreaks, shifts in protein demand, and regulatory constraints that can affect product usage and farm economics. Its global footprint also creates exposure to import restrictions, sanctions, foreign exchange, cybersecurity, and integration or execution risk around acquisitions and new product lines.
- Animal disease outbreaksImpact: HighLikelihood: Medium
Disease events can change treatment patterns, herd sizes, and customer purchasing behavior.
Exposure: Livestock and aquaculture markets
- Demand swings in animal proteinImpact: HighLikelihood: Medium
Lower protein consumption can lead producers to reduce herd or flock sizes and cut product usage.
Exposure - Regulatory and import restrictionsImpact: MediumLikelihood: Medium
Animal health products are subject to local approvals, import rules, and extra-label use limits.
Exposure: Asia Pacific and other regulated markets
- Cybersecurity and IT disruptionImpact: MediumLikelihood: Medium
Operational systems support manufacturing, sales, and technical services, so breaches can disrupt business.
Exposure: Global operations
- Foreign exchange and geopolitical exposureImpact: MediumLikelihood: Medium
International sales and intercompany activity create currency and sanctions-related volatility.
Exposure
Accounting
Judgemental itemsThe company carries goodwill and identifiable intangibles that require judgmental impairment testing.
Impact: Write-downs could materially affect earnings and equity.
Purchased product portfolios and businesses create valuation and integration accounting complexity.
Impact: Affects amortization, purchase accounting, and non-GAAP adjustments.
International operations and intercompany balances create currency exposure.
Impact: Can create volatility in reported operating results.
Livestock demand, import timing, and large-customer ordering patterns can shift quarterly revenue.
Impact: Makes quarter-to-quarter comparisons less linear.
Similar listed companies
Publicly listed companies with a comparable business focus.
Elanco Animal Health Inc
ELAN · Pharmaceutical Preparations
Elanco Animal Health is a U.S.-based animal health company that develops and sells medicines, vaccines, feed additives and related services for pets and farm animals.
Phio Pharmaceuticals Corp.
PHIO · Pharmaceutical Preparations
Pilgrim's Pride Corporation
PPC · Poultry Slaughtering and Processing
Zoetis Inc.
ZTS · Pharmaceutical Preparations
Merck & Co., Inc.
MRK · Pharmaceutical Preparations
Thermo Fisher Scientific Inc
TMO · Measuring & Controlling Devices, NEC
Thermo Fisher Scientific is a U.S.-based life sciences and laboratory company organized around four segments: Life Sciences Solutions, Analytical Instruments,…
Last updated: 24/09/2026